B
Bull
Bull · 25%APLS
$26.85
情境價格
$41.030
-0.029 (-0.07%)收盤時
Loading chart…
- High
- 41.070
- Open
- 41.050
- VWAP
- 41.04
- Vol
- 68.61M
- Mkt Cap
- 5.04B
- Low
- 41.030
- Amount
- 2.82B
- EV/EBITDA, TTM
- 52.52
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Analyst Ratings (3)
-22.76% downside
Buy
3 Buy
0 Hold
0 Sell
Current: 41.03
最低
19.00
平均
31.69
最高
48.00
Wells Fargo
Equal Weight
$41
2026-04-17
Wells Fargo
2026-04-17
目標價
$41
Equal Weight
RBC Capital
Sector Perform
$41
2026-04-07
RBC Capital
2026-04-07
目標價
$41
Sector Perform
Mizuho
Neutral
$41
2026-04-02
Mizuho
2026-04-02
目標價
$41
Neutral
Roth Capital
Neutral
$41
2026-04-02
Roth Capital
2026-04-02
目標價
$41
Neutral
JPMorgan
Neutral
$41
2026-04-01
JPMorgan
2026-04-01
目標價
$41
Neutral
估值指標
The current forward P/E ratio for Apellis Pharmaceuticals Inc (APLS) is 46.30, compared to its 5-year average forward P/E of -24.34.
Alphio AI Price Scenarios for APLS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding APLS
事件時間軸
資訊
8.506-05stocktwitsPharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs
8.505-14GlobenewswireBiogen Completes Acquisition of Apellis Pharmaceuticals
8.505-14NewsfilterBiogen Completes Acquisition of Apellis Pharmaceuticals
4.505-07moomooS&P Dow Jones Indices: Bright Horizons Family Solutions and Remitly Global to be Added to S&P SmallCap 600
4.505-06NASDAQ.COMAnalysis of XBI ETF Trading Dynamics
APLS FAQ — answered by Alphio AI
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
3 analysts cover APLS: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.69.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。